title: Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome.
abstract: The metabolic syndrome (MS) poses an increased risk for the development of diabetes mellitus and cardiovascular events. The syndrome typically includes dyslipidemia, characterized by elevated plasma triglycerides and low high-density lipoprotein cholesterol concentrations. Retrospective analyses of coronary artery disease outcomes trials in patient subpopulations with diabetes or the MS indicate that lipid-altering therapies provide benefits for patients with the MS at least as much as observed in patients without diabetes or the MS. Analyses of the effects of lipid-altering therapy on the lipid profile in patients with the MS also indicate that beneficial lipid changes are similar in patients with the MS compared with those in patients without the MS. The benefits of statin treatment in patients with the MS have become increasingly clear, and it is likely that further improvements in treatment may be achieved with newer statins or a combination of lipid-altering drugs. Prospective data from clinical trials examining the preventive effects of lipid-altering therapy in MS patients are needed to better define potential benefits and optimal treatment in this population.
authors.affiliation: formerly with the Heart Disease Prevention Clinic, University of Minnesota, Minneapolis, Minnesota, USA. deed@ucsfresno.edu
authors.forename: Prakash C
authors.initials: PC
authors.lastname: Deedwania
authors.forename: Donald B
authors.initials: DB
authors.lastname: Hunninghake
authors.forename: Harold
authors.initials: H
authors.lastname: Bays
mesh_terms: D000328:Adult; D008076:Cholesterol, HDL / Q000032:analysis / Q000187:drug effects; D008078:Cholesterol, LDL / Q000032:analysis / Q000187:drug effects; D015897:Comorbidity; D003327:Coronary Disease / Q000517:prevention & control*; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D024821:Metabolic Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors